Genexine Inc Market Cap ($63.49 Million)
Market Cap & Net Worth: Genexine Inc (095700)
Genexine Inc market cap. Genexine Inc (KQ:095700) has a market capitalization of $63.49 Million (₩93.69 Billion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #20778 globally and #1161 in its home market, demonstrating a -13.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genexine Inc's stock price ₩2060.00 by its total outstanding shares 45479667 (45.48 Million). Also see 095700 cash generation efficiency for how efficiently the company converts equity into cash flow.
Genexine Inc Market Cap History (2015–2026)
Genexine Inc market cap history from 2015 to 2026. Data shows change from $1.04 Billion to $63.49 Million (-21.48% CAGR). Check Genexine Inc (095700) share price today for real-time trading data and today's change.
Index Memberships
Genexine Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$203.83 Billion | 0.03% | #515 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$203.83 Billion | 0.03% | #515 of 1384 |
Weight: Genexine Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Genexine Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genexine Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 095700 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.06x
Genexine Inc's market cap is 0.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.04 Billion | $32.52 Billion | -$1.43 Billion | 0.03x | N/A |
| 2016 | $955.47 Million | $11.35 Billion | -$30.93 Billion | 0.08x | N/A |
| 2017 | $1.62 Billion | $28.45 Billion | -$19.33 Billion | 0.06x | N/A |
| 2018 | $1.61 Billion | $12.88 Billion | -$34.07 Billion | 0.12x | N/A |
| 2019 | $1.38 Billion | $11.30 Billion | -$16.51 Billion | 0.12x | N/A |
| 2020 | $2.75 Billion | $18.54 Billion | $27.57 Billion | 0.15x | 0.10x |
| 2021 | $1.29 Billion | $36.83 Billion | -$47.73 Billion | 0.04x | N/A |
| 2022 | $443.35 Million | $16.14 Billion | -$56.27 Billion | 0.03x | N/A |
| 2023 | $305.13 Million | $4.43 Billion | -$66.87 Billion | 0.07x | N/A |
| 2024 | $164.58 Million | $2.93 Billion | -$63.71 Billion | 0.06x | N/A |
Competitor Companies of 095700 by Market Capitalization
Companies near Genexine Inc in the global market cap rankings as of November 4, 2026. Also see Genexine Inc (095700) total assets for a full breakdown of the balance sheet.
Key companies related to Genexine Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Genexine Inc (2015–2026)
Market capitalization of Genexine Inc from 2015 to today. Between 2015 and today, Genexine Inc's market cap moved from $1.04 Billion to $ 63.49 Million, with a yearly change of -21.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩63.49 Million | -56.03% |
| 2025 | ₩144.40 Million | -12.27% |
| 2024 | ₩164.58 Million | -46.06% |
| 2023 | ₩305.13 Million | -31.18% |
| 2022 | ₩443.35 Million | -65.66% |
| 2021 | ₩1.29 Billion | -53.10% |
| 2020 | ₩2.75 Billion | +98.88% |
| 2019 | ₩1.38 Billion | -13.91% |
| 2018 | ₩1.61 Billion | -0.55% |
| 2017 | ₩1.62 Billion | +69.18% |
| 2016 | ₩955.47 Million | -8.09% |
| 2015 | ₩1.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Genexine Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $63.49 Million USD |
| MoneyControl | $63.49 Million USD |
| MarketWatch | $63.49 Million USD |
| marketcap.company | $63.49 Million USD |
| Reuters | $63.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genexine Inc
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses… Read more